Two recent studies expand the list of conditions that may benefit from GLP‑1 medications, already praised for helping millions lose weight and manage Type 2 diabetes. The first study, published in a peer‑reviewed journal, found that the GLP‑1 drugs liraglutide and semaglutide significantly improved remission rates in patients with ulcerative colitis (UC) after just four weeks of treatment. By the 12‑week mark, participants reported a 60% to 72% reduction in UC symptoms, a notable achievement for a disease that is often difficult to control.
Cardiovascular advantage for those with serious mental illness
A separate investigation appearing in JAMA Psychiatry compared the long‑term heart‑health outcomes of GLP‑1 therapy with those of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors, such as Jardiance, in individuals diagnosed with serious mental illness. Over a four‑year follow‑up period, patients who started on GLP‑1 agents experienced a statistically significant lower risk of major cardiovascular events and death compared with those on SGLT2 inhibitors. Even after just one year, all‑cause mortality was 49% lower among the GLP‑1 group.
What this means for patients
For people who are overweight or obese, have Type 2 diabetes, and also struggle with ulcerative colitis or serious mental health conditions, these findings suggest an additional therapeutic option. Physicians may consider discussing GLP‑1 therapy as part of a comprehensive treatment plan that addresses weight management, glycemic control, gastrointestinal health, and cardiovascular risk.
Broader context of GLP‑1 research
Beyond the two studies highlighted here, GLP‑1 drugs have been linked to potential benefits in a range of other health areas, including recovery from alcohol use disorder, reduced progression risk for early‑stage lung, breast, colorectal and liver cancers, and improved outcomes for patients with chronic kidney disease, arthritis, sleep apnea, and various cardiovascular conditions. While many of these associations are still under investigation, the growing body of evidence underscores the versatility of GLP‑1 therapy.
Practical steps for readers
Anyone interested in exploring GLP‑1 treatment should consult their primary care provider or endocrinologist. A thorough evaluation of medical history, current medications, and specific health goals will help determine whether a GLP‑1 agent is appropriate. Patients are also encouraged to maintain a balanced diet, regular physical activity, and routine monitoring of blood glucose and weight.
Resources
For additional guidance on managing Type 2 diabetes, achieving a healthy weight, and navigating gastrointestinal disorders, readers may find the books “YOU: The Owner’s Manual, Revised” and “What to Eat When” useful. Health pioneer Dr. Michael Roizen, M.D., also offers further insights in his recent publication, “The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow,” available at www.4YOUngevity.com.
Original reporting: Texarkana Gazette — read the source article.
